DepartmentMicrobiology, Immunology & Molecular Genetics
Dr. Bernard Arulanandam is the Interim Vice President for Research, Economic Development and Knowledge Enterprise at The University of Texas at San Antonio (UTSA). He is an established Immunologist and directs a research program that is focused on elucidating host-microbial interactions and the cellular & molecular mechanisms involved in the induction of immune responses against infectious diseases. Work from his laboratory have provided new insights into the development of vaccines against Chlamydia trachomatis, the leading cause of sexually transmitted bacterial disease and the creation of a potential live attenuated vaccine against multidrug-resistant Acinetobacter baumannii identified as an important nosocomial pathogen. His research has also advanced several animal models for vaccine development against Francisella tularensis. Dr. Arulanandam’s interdisciplinary research accomplishments are demonstrated by his funding from the National Institutes of Health, Department of Defense, and Department of Homeland Security, extensive list of research publications and issued patents. Dr. Arulanandam has successfully mentored many students and post-doctoral fellows who have now developed independent productive careers in government, industry and academia.
From 2012 to 2016, Dr. Arulanandam served as the Director of the South Texas Center of Emerging Infectious Diseases and currently is also the Scientific Director of the Vaccine Development Center of San Antonio. Dr. Arulanandam serves as the Councilor for the Oak Ridge Association of Universities, a member of the Board of Directors for Biomed SA and represents UTSA at the UT System Office of Federal Relations National Security Advisory Group (NSAG).
Dr. Bernard Arulanandam obtained a Ph.D. in Microbiology and Immunology at the Medical College of Ohio and received a postdoctoral fellowship at the Albany Medical College in New York and an executive M.B.A. at The University of Texas at San Antonio.